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Abstract. Background/Aim: The aim of this study was to
analyze the prognostic impact of biomarkers, such as serum
lactate dehydrogenase (LDH), in patients with oligometastatic
castration-resistant prostate cancer, arbitrarily defined as a
maximum of five metastatic lesions. Patients and Methods:
This was a retrospective single-institution analysis. Overall 34
patients were included, all of whom received first-line
docetaxel without ablative local treatment. Results: Twelve
patients (35%) had elevated LDH (≥255 U/l). Their median
survival was significantly shorter than that of patients with
normal LDH. Due to an interaction with other biomarkers,
multivariate Cox regression analysis was performed. The
latter showed that serum hemoglobin was the only
significant predictor of survival. Conclusion: Correct
diagnosis of oligometastatic disease is not trivial, because
all radiological modalities are limited by certain thresholds
for detection of small metastases. Serum biomarkers may
reflect the total burden of malignant disease. However, this
relatively small study did not clearly demonstrate that
elevation of LDH may be useful for clinical decision-making,
e.g. in terms of adding local treatment for all sites of
metastatic spread. 
Increasing attention has recently been paid to patients with
oligometastatic disease, i.e. a state between curable
locoregional disease and incurable dissemination throughout
large parts of the body (1-4). If only few distant metastases
are present, ablative local treatment or resection of all these
lesions might result in longer survival than historically
observed (5-7). However, not all patients become long-term
survivors, a finding that emphasizes the challenges
associated with detecting true oligometastatic disease. If
additional micrometastases go undetected, rapid disease
progression might be encountered. It would, therefore, be
prudent to include staging examinations that are not limited
by the detection thresholds of radiological methods (8-10).
For example, the number of circulating tumor cells, cell-free
DNA or other emerging biomarkers may aid in the detection
of true and pseudo-oligometastatic disease (11, 12). Given
that many patients, especially in low- and middle-income
countries, lack access to advanced imaging and biomarker
evaluations, widely available and inexpensive biomarkers
may also contribute to improved prognostic assessment and
decision-making. Therefore, we studied the prognostic
impact of serum lactate dehydrogenase (LDH), prostate-
specific antigen (PSA), alkaline phosphatase (ALP) and
hemoglobin in patients with oligometastatic castration-
resistant prostate cancer (MCRPC) who received first-line
chemotherapy with docetaxel. We hypothesized that such
biomarkers might reflect the overall disease burden in
patients presumed to harbor oligometastases. If true, patients
with elevated serum biomarkers due to otherwise
undetectable additional metastases are expected to have
poorer survival and may be spared the burden of aggressive
local treatment.
Patients and Methods
Patients and treatment. A retrospective study of all patients with
MCRPC and a maximum of five distant metastases treated with
first-line docetaxel at our hospital was performed. An existing
database was used to identify eligible patients (13). These patients
had not received docetaxel for hormone-sensitive metastatic
disease earlier. Further treatment was individualized and consisted
of additional lines of systemic therapy (Ra-223, enzalutamide,
abiraterone acetate, cabazitaxel) or best supportive care. Systemic
treatment was usually prescribed as judged appropriate by the
patients’ clinical oncologists and was tailored to performance
status (typically 0-1), organ function and comorbidity. The patients
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were treated between January 01, 2007 and December 31, 2017.
Staging consisted of computed tomography and bone isotope scan.
Biomarkers were assessed at the start of chemotherapy or within
the preceding week (the normal value was defined as <255 U/l for
LDH, <105 U/l for ALP, and 13.4-17.0 g/dl for hemoglobin).
Statistical methods. Overall survival (time to death) from the first
day of chemotherapy was calculated employing the Kaplan–Meier
method, and different groups were compared using the log-rank test
(SPSS 25; IBM Corp., Armonk, NY, USA). Only four patients were
censored after a median follow-up of 48 months. Date of death was
known for all other patients. A Cox forward conditional regression
model was employed for multivariate analysis. Statistical
significance was defined as p<0.05 throughout this study. 
Results
Patient characteristics. A total of 34 patients were identified
from the database. Their median age was 69 (range=56-78)
years. Six patients (18%) already had distant metastases
when diagnosed with prostate cancer, the others developed
metachronous metastases. Nine patients (26%) had pelvic
lymph node metastases (N+ disease) at first diagnosis.
Thirteen patients (38%) were initially treated with curative
radiotherapy or radical prostatectomy. Two patients (6%)
received palliative radiotherapy to the prostate before
chemotherapy. Further patient characteristics are shown in
Table I. 
Treatment for MCRPC. Twenty patients (59%) received
docetaxel every 3 weeks (75 mg/m2) and the remainder
every 2 weeks or every week at lower doses.
Oligometastases were not treated with local measures such
as surgery or ablative radiotherapy. Bisphosphonates were
given to 11 patients (32%) concomitant to chemotherapy.
Except for nine patients (26%), further systemic treatment
with approved agents (Ra-223, enzalutamide, abiraterone
acetate, cabazitaxel) was given after disease progression
on docetaxel (14). 
Survival. The median overall survival of the whole patient
cohort was 27.7 months. As shown in Figure 1, LDH was
significantly associated with survival. Survival beyond 5 years
was observed in patients with normal LDH only. Survival was
not significantly associated with previous treatment of the
primary tumor (surgery or curative radiotherapy vs. none),
bisphosphonate use, patterns of metastasis (bone only, lymph
nodes only etc.), age, ALP and PSA. However, patients with
a normal hemoglobin level survived significantly longer than
their counterparts with abnormally low values. In the Cox
regression model, hemoglobin retained statistical significance
(p=0.008), whereas LDH did not (p=0.21). 
Discussion
We performed a retrospective study on patients with a
limited number of distant metastases (maximum five in total)
and evaluated biomarkers which previously have been
studied in different other settings (15, 16). We found that
elevated LDH and reduced hemoglobin were associated with
significantly shorter survival, however in multivariate
analysis, hemoglobin outperformed LDH. 
Limitations of the present study include the limited number
of patients, statistical power of subgroup analyses, and
retrospective design. The presence of oligometastatic disease was
not confirmed by positron-emission tomography (PET) staging.
However, PET staging is also associated with false-negative and
otherwise inaccurate findings (7). Moreover, the availability of
PET is limited or, in some low- and middle-income countries,
even non-existent. Under these circumstances, readily available
biomarkers might complement computed tomographic- and
isotope scan-based staging, with the ultimate goal of avoiding
overtreatment in patients with pseudo-oligometastatic disease.
Emerging biomarkers such as those based on circulating tumor
cells are not widely available yet (17), in contrast to hemoglobin,
LDH or ALP measurement. 
We limited this analysis to patients treated with first-line
docetaxel rather than a variety of different approved options
in order to eliminate bias arising from differences in first-line
systemic treatment. As recently discussed by different groups,
aggressive local treatment of oligometastatic cancer is
expected to improve survival (2-4, 18). Even in the absence
of metastasis-directed local treatment, we found long-term
survivors in the group with normal hemoglobin (and also
LDH). Our results suggest that readily available blood tests
may add value when designing further clinical trials and in
resource-limited settings.    
Conclusion
Correct diagnosis of oligometastatic disease is not trivial
because all radiological modalities are limited by certain
thresholds for the detection of small metastases. Serum
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Table I. Patient characteristics.
Baseline parameter                                                             Value
Bone metastases only, n (%)                                            16 (47)
Lymph node metastases only, n (%)                                 9 (26)
Visceral metastases only, n (%)                                         2 (6)
Bone and lymph node metastases, n (%)                         7 (21)
Median serum PSA (range), μg/l                                 93 (6-1487)
Median serum ALP (range), U/l                                 123 (47-916)
Median serum LDH (range), U/l                               211 (146-675)
Median hemoglobin (range), g/dl                              13.6 (9.6-16.0)
ALP: Alkaline phosphatase; LDH: lactate dehydrogenase; PSA:
prostate-specific antigen.
biomarkers may reflect the total burden of malignant disease.
However, this relatively small study did not clearly
demonstrate that elevation of LDH may be useful for clinical
decision-making, e.g. in terms of adding local treatment for
all sites of metastatic spread.     
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